AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer-May 2024-www.financetom.com

AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

AstraZeneca's Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer

Jun 16, 2024 11:45 PM

June 17 (Reuters) - AstraZeneca's ( AZN ) blockbuster

cancer drug Imfinzi combined with chemotherapy has been approved

in the U.S. as treatment for adult patients with primary,

advanced or recurrent endometrial cancer that is mismatch repair

deficient, the drugmaker said.

Previous page： Kotak Mahindra Bank Q4 profit rises 36% to Rs 2,589 cr Next page： Steel prices go up by Rs 3,500-4,500 per tonne in May, says JP Morgan

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Kotak Mahindra Bank Q4 profit rises 36% to Rs 2,589 cr

May 3, 2021

On the COVID-19 impact, it said, the bank continues to closely monitor the situation and in response to this health crisis it has implemented protocols and processes to execute the business continuity plans and help protect its employees and support its clients.

Steel prices go up by Rs 3,500-4,500 per tonne in May, says JP Morgan

May 3, 2021

Steel stocks are higher in trade. The street was bracing for a price hike at the start of May and that is what precisely has happened.

Aspire to grow faster than the industry: Marico

May 3, 2021

Marico reported strong Q4FY21 earnings. Speaking to CNBC-TV18, MD and CEO Saugata Gupta said, “Broadly the last 3-4 year trend in the sector, the growth has been 6-7 percent so we are targeting an aspirational number of slightly higher than the sector average.”

Kotak Mahindra Q4 earnings: Prakash Diwan says sub optimal NII a cause of concern on valuations

May 3, 2021

Kotak Mahindra Bank Q4FY21 net profits are below estimates at Rs 1,682 crore. Asset quality too has deteriorated and the...